News

The study was first presented to the scientific community on October 14, 2014 at the World Vaccine Congress in Brussels, Belgium by Vaxart. WCCT Global conducted this phase

The randomized, double-blind, placebo-controlled study, known as "EASE LID 3," is planned to enroll approximately 70 patients with LID. The 13-week study will include an estimated 35 sites

Fleet’s management team, along with several additional investors, will hold minority stakes alongside Gryphon. Fleet Laboratories, headquartered in Lynchburg, VA and family-owned since its founding in 1869, is

Americans catch an estimated 1 billion colds annually. During cold and flu season, the Centers for Disease Control and Prevention estimates that as many as 20 percent of

FS102 is being developed to treat breast and gastric cancer in HER2-positive patients who do not respond or become resistant to the existing therapies. HER2, a highly validated

The IND was based on a pivotal Phase III protocol for Neutrolin in hemodialysis patients with a central venous catheter. The multi-center, randomized, controlled Phase III clinical trial

Funded by the EU Innovative Medicines Initiative (IMI), the consortium aims to define a standard for the responsible use of dwindling reserves of effective antibiotics. The new consortium

Under the deal, LLR will provide access to new therapies currently being researched by its scientists, as well as offer financial support for Cancer Research UK to develop

MuGard is designed to manage oral mucositis by forming a protective hydrogel coating over the oral mucosa to shield the membranes of the mouth and tongue. PlasmaTech Biopharmaceuticals